Paper Details

  1. Home
  2. Paper Details

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study.

Author: Abud-MendozaCarlos, ArandaRichard, BoxJane, DelaetIngrid, ElizondoMario Garza, GujrathiSheila, KeystoneEdward Clark, KremerJoel M, LuggenMichael, LuoAllison, RussellAnthony, SwaninkRene

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Switching from long-term intravenous abatacept to a weekly fixed dose of 125 mg SC abatacept was found to be safe and effective in patients with rheumatoid arthritis. No increased safety concerns were observed.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess safety, immunogenicity and efficacy in rheumatoid arthritis (RA) patients switched from long-term intravenous to subcutaneous (SC) abatacept. METHODS: In this phase IIIb, open-label, single-arm trial, patients who completed ≥4 years of intravenous abatacept (in long-term extens...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/annrheumdis-2011-200355

データ提供：米国国立医学図書館（NLM）

Navigating the Sands of Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects the joints. It can be a tough journey for patients, like a camel struggling through a scorching desert! This study explores the safety and efficacy of switching from intravenous to subcutaneous abatacept, a medication used to treat RA.

Switching to Subcutaneous Abatacept for RA

The study found that patients with RA who switched from intravenous to subcutaneous abatacept experienced no significant increase in safety concerns. The efficacy of the medication remained consistent, offering a convenient alternative for patients. This is like finding a cooler and more comfortable way to travel through the desert, making the journey easier and more manageable.

A New Option for RA Patients

This research provides evidence that switching from intravenous to subcutaneous abatacept is a safe and effective option for RA patients. This could make treatment more convenient for patients and potentially improve their quality of life. This is a step forward in the quest for better RA treatments, and it's a reminder that even in the vast desert of chronic diseases, we can find new ways to improve patient care.

Dr.Camel's Conclusion

This study provides valuable insights into the safety and efficacy of switching from intravenous to subcutaneous abatacept for RA patients. It offers a promising alternative for patients seeking a more convenient and effective treatment option. This research continues the journey towards better RA management, offering hope and new possibilities for those navigating the desert of this debilitating disease.

Date :
  1. Date Completed 2012-07-03
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

22302417

DOI: Digital Object Identifier

10.1136/annrheumdis-2011-200355

Related Literature

Article Analysis
・Effects of abatacept injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.